$2.98
1.65% day before yesterday
Nasdaq, Dec 27, 09:50 pm CET
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

AbCellera Biologics Inc Stock price

$2.99
-0.01 0.33% 1M
+0.11 3.82% 6M
-2.72 47.64% YTD
-2.81 48.45% 1Y
-11.76 79.73% 3Y
-17.01 85.05% 5Y
-17.01 85.05% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.04 1.32%
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

Key metrics

Market capitalization $883.14m
Enterprise Value $286.40m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.69
P/S ratio (TTM) P/S ratio 26.79
P/B ratio (TTM) P/B ratio 0.82
Revenue growth (TTM) Revenue growth -34.59%
Revenue (TTM) Revenue $32.96m
EBIT (operating result TTM) EBIT $-308.06m
Free Cash Flow (TTM) Free Cash Flow $-195.27m
Cash position $668.14m
EPS (TTM) EPS $-0.60
P/E forward negative
P/S forward 27.96
EV/Sales forward 9.07
Short interest 7.14%
Show more

Is AbCellera Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

AbCellera Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AbCellera Biologics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a AbCellera Biologics Inc forecast:

Buy
89%
Hold
11%

Financial data from AbCellera Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
33 33
35% 35%
100%
- Direct Costs 92 92
-
280%
-59 -59
-
-180%
- Selling and Administrative Expenses - -
- Research and Development Expense 170 170
9% 9%
515%
-216 -216
27% 27%
-655%
- Depreciation and Amortization 92 92
148% 148%
280%
EBIT (Operating Income) EBIT -308 -308
49% 49%
-935%
Net Profit -176 -176
36% 36%
-533%

In millions USD.

Don't miss a Thing! We will send you all news about AbCellera Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbCellera Biologics Inc Stock News

Positive
Seeking Alpha
5 days ago
Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet.
Neutral
Business Wire
about one month ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in December and January.
Neutral
Business Wire
about 2 months ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024.
More AbCellera Biologics Inc News

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Carl Hansen
Employees 586
Founded 2012
Website www.abcellera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today